Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;10(6):409-10.
doi: 10.1038/nrd3462.

US academic drug discovery

Stephen Frye, Marina Crosby, Teresa Edwards, Rudolph Juliano

US academic drug discovery

Stephen Frye et al. Nat Rev Drug Discov. 2011 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Therapeutic (A) and target-class focus (B) (see supplemental information, survey questions 14 and 15). The undisclosed targets result from a small number of centers providing no information. (C) Sources of hits by discovery strategy. The figure indicates tractable hits that originated from each strategy averaged over all respondents (see supplemental information, survey question 19).
Figure 1
Figure 1
Therapeutic (A) and target-class focus (B) (see supplemental information, survey questions 14 and 15). The undisclosed targets result from a small number of centers providing no information. (C) Sources of hits by discovery strategy. The figure indicates tractable hits that originated from each strategy averaged over all respondents (see supplemental information, survey question 19).
Figure 1
Figure 1
Therapeutic (A) and target-class focus (B) (see supplemental information, survey questions 14 and 15). The undisclosed targets result from a small number of centers providing no information. (C) Sources of hits by discovery strategy. The figure indicates tractable hits that originated from each strategy averaged over all respondents (see supplemental information, survey question 19).
Figure 2A
Figure 2A
Degree of validation of target portfolios. Responders were asked to give the approximate percentage of their center's targets in three categories: innovative targets based on unique discoveries or expertise within your institution with little validation evidence in the literature (“Innovative” above); targets with significant pre-clinical evidence for validity in the literature but lacking clinical validation (“Preclinical Val” above); targets with existing clinical evidence of validity (“Clinical Val” above); or they could choose not to answer (“Undisclosed” above) (see supplemental information, survey question 16).
Figure 2B
Figure 2B
Aggregated depiction of the drug discovery pipeline by stage for all centers. Note: the mean number of instances in each drug discovery stage was calculated with the mid points of the ranges reported (see supplemental information, survey questions 18, 20 & 21).
See this image and copyright information in PMC

References

    1. Schreiber SL. Small molecules: the missing link in the central dogma. Nat Chem Biol. 2005;1:64–66. - PubMed
    1. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959–68. - PubMed
    1. Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9:203–214. - PubMed
    1. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006;116:2837–42. - PMC - PubMed
    1. Stevens AJ, et al. The Role of Public-Sector Research in the Discovery of Drugs and Vaccines. New England Journal of Medicine. 2011;364:535–541. - PubMed